Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leadership & People

Set Alert for Leadership & People

Executives On The Move: NervGen Pharma, Janux Therapeutics and More

Recent executive moves in the industry include C-suite changes at NervGen Pharma and Phathom Pharmaceuticals and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Janux Therapeutics and PepGen.

Executive Changes Leadership

Chinese-Language Podcast: ESMO上的中国数据

Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.

China Clinical Trials

Pharma Past Propels Julie Brown To GSK’s CFO Position

GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.

Executive Changes Leadership

Executives On The Move: New Roles Filled at Lisata Therapeutics, Roquefort Therapeutics and Voyager Therapeutics

This week's executive changes in the industry include new CEOs at Roquefort Therapeutics, Lisata Therapeutics and Everest Medicines, while Vyriad and RenovoRx get new chief operating officers. 

Executive Changes Leadership

New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal

Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.

Companies Research & Development

Novo Nordisk Committed To Advancing In Cardiovascular

The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.

Cardiovascular Business Strategies

Executives On The Move: Metagenomi, Psilotech Health Solutions and More

Recent executive changes in the industry include C-suite changes at TherapeuticsMD and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Metagenomi and Psilotech Health Solutions.

Executive Changes Leadership

Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.

Companies Cancer

Executives On The Move: Precision Biosciences, Revolution Medicines and More

Recent executive changes in the industry include C-suite changes at Precision Biosciences and Revolution Medicines. Meanwhile, new directors were appointed at Sanofi and Arcutis Biotherapeutics.

Executive Changes Leadership

From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug Development

Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.

China Cancer

Architect Of Keytruda Reflects On A Great Scientific Success Story

Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.

ImmunoOncology Strategy

Executives On The Move: Altius Healthcare, Aeglea Biosciences And More

Recent executive changes in the industry include C-suite changes at Aeglea Biosciences and I-Mab. Meanwhile, new directors were appointed at Altius Healthcare and Vaxart.

Executive Changes Leadership
See All